Makaleler
85
Tümü (85)
SCI-E, SSCI, AHCI (73)
SCI-E, SSCI, AHCI, ESCI (79)
ESCI (5)
Scopus (76)
TRDizin (11)
35. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives
European Archives of Oto-Rhino-Laryngology
, cilt.280, sa.8, ss.3541-3556, 2023 (SCI-Expanded, Scopus)
37. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded)
41. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma
European Archives of Oto-Rhino-Laryngology
, cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded, Scopus)
54. Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
Schmid P., Sohn J. H., Jerez Gilarranz Y., Gonzalez-Cortijo L., Sonnenblick A., Sabanathan D., et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
, cilt.18, ss.233-234, 2022 (SCI-Expanded)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
66
1. Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
3. Reirradiation with Stereotactic Ablative Radiotherapy in Recurrent Nasopharyngeal Carcinoma
9th International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO), Barcelona, İspanya, 21 - 23 Mart 2024, (Özet Bildiri)
4. Reirradiation With Stereotactic Ablative Radiotherapy In Recurrent Head And Neck Cancers
9th International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO), Barcelona, İspanya, 21 - 23 Mart 2024, (Özet Bildiri)
10. Trace-Level Determination of 2-Amino Adipic Acid by LC-ESI-MS/MS for Early Diagnosis of Breast Cancer
International Trace Analysis Congress, 20 - 23 Haziran 2018, (Özet Bildiri) 
11. Mass Spectrometry Based Targeted and Untargeted Metabolomic Analysis for Early Diagnosis of Breast Cancer Using LC-ESI-qTOF-MS and LC-ESI-MS/MS
8TH 8th BLACK SEA BASIN CONFERENCE ON ANALYTICAL CHEMISTRY, 9 - 11 Mayıs 2018, (Özet Bildiri)
12. Adjuvan Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanserli Olgularda Tedavi Sonuçlarımız.
13.Ulusal Radyasyon Onkolojisi Kongresi, Türkiye, 27 Nisan - 01 Mayıs 2018, (Tam Metin Bildiri)
21. Effect of body mass index in the outcome of stage I III triplenegative breast cancer
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
22. Effect of using different antihypertensive drugs ondemographic and clinico pathological characteristics ofbreast cancer
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
23. Effect of polypharmacy on treatment preferences andoutcome in older breast cancer patients
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
24. Effect of using different antidiabetic drugs on demographicand clinico pathological characteristics of breast cancer
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
27. The impact of the total size of lesions in multifocal multicentric breast cancer on survival
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
30. Modified docetaxel cisplatin and fluorouracil therapy as a first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer a retrospective study
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
36. Study of the impact of Charlson comorbidity index on the efficacy of aromatase inhibitors in patients with hormone receptor positive postmenopausal breast cancer
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
37. Neuroendocrine breast cancer A single center experience
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
39. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
47. Inflammatory markers in metastatic breast cancer.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
48. Metformin in diabetic pancreatic cancer patients: Benefit or not-Multicenter experience.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
49. Retrospective analysis of 178 patients with stage I rectum cancer.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
50. Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
51. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
52. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
53. Retrospective review of modified dose docetaxel, cisplatin, and 5-flourouracil (DCF) for the treatment of first-line metastatic gastric carcinomas.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
54. Comparison of the efficacy of adjuvant letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
55. Clinicopathologic characteristics of pure papillary breast carcinoma
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
56. Inflammatory markers in early-stage breast cancer.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
57. Demographic and clinicopathologic characteristics in patients with invasive breast cancer receiving metformin.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
58. The number of metastatic lymph node in N3M0 breast cancer and influence on survival.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
60. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
62. Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
63. Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
64. Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
66. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.202, (Özet Bildiri)
Kitaplar
5
5. Current Systemic Therapy Options for Head and Neck Cancer
Radiation Therapy for Head and Neck CancersA Case Based Review, Murat Beyzade, Gökhan Ozyigit, ugur Selek, Editör, Springer, 2015
Metrikler
Yayın
306
Açık Erişim
55
BM Sürdürülebilir Kalkınma Amaçları
